PMN ProMIS Neurosciences Inc.

BEARISH Impact: 7/10 EFFECT
Horizon days Filed Apr 3, 2026 Processed 2mo ago SEC 9999999995-26-001071
IPO/offering going effective
Latest settled — T+20d
PMN ▲ +1.00% at T+20d
SHORT call ✗ call lost -1.00% · α vs SPY +7.98% · entry $10.96 → $11.07
Next anchor: T+60d in 20d
Currently $9.74 · +11.09% from $10.96 entry (call sign-flipped)
Entry anchored
Apr 2, 03:53 PM ET
via Databento tick
T+1d
-0.73%
call +0.73% · α +0.79%
$10.88
settled 2mo ago
T+5d
+17.88%
call -17.88% · α -13.75%
$12.92
settled 2mo ago
T+20d
+1.00%
call -1.00% · α +7.98%
$11.07
settled 6w ago
T+60d
call — · α —
in 20d

Price Chart

Loading chart...

Executive Summary

ProMIS Neurosciences' S-3 shelf registration has become effective, allowing the company to raise up to $200 million through various securities, including a $50 million ATM offering. This creates a potential for near-term dilution, especially given the company's $112 million market cap and recent history of share issuances. The effectiveness follows two prior S-3 filings within the last 16 days, signaling aggressive capital-raising activity.

Actionable Insight

Traders should monitor for imminent share issuance, particularly under the $50 million ATM program, which could pressure the stock price. The repeated shelf filings in quick succession suggest urgent funding needs, increasing the likelihood of near-term dilution. Consider hedging or reducing exposure ahead of expected offerings.

Key Facts

  • S-3 shelf registration (File No. 333-294610) became effective on 2026-04-02
  • Registration allows ProMIS to raise up to $200 million through debt, equity, or hybrid securities
  • Includes a $50 million ATM offering facility with H.C. Wainwright
  • Company market cap is $112 million, meaning even modest offerings represent significant dilution
  • This is the third S-3-related filing in 16 days, indicating urgent capital needs

Financial Impact

Up to $200 million in potential dilution; $50 million ATM offering alone would increase shares outstanding by over 44% at current market cap

dilutionmarketCapsharePriceequityValue

Risk Factors

  • Significant share dilution from ATM or other offerings under the shelf
  • Downward pressure on stock price due to oversupply of shares
  • Potential for insider selling coinciding with new issuance

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001071
Document: 9999999995-26-001071-index.html9999999995-26-001071
Document: 9999999995-26-001071.txt9999999995-26-001071
5 reports for PMN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PMN — sortable, filterable
Type Now
May 28, 2026
12d ago
Press Release
NEUTRAL ★ 3/10
$10.87 $9.65▼ −11.22%▼ −11.18%$9.74 (−10.35%)
May 12, 2026
28d ago
8-K
NEUTRAL ★ 4/10
$10.49 $10.44▼ −0.48%▼ −0.55%$9.74 (−7.10%)
Apr 3, 2026
9w ago
EFFECT
BEARISH ★ 7/10
$10.96 $12.92▼ −17.88%▼ −13.75%$9.74 (+11.09%)
Mar 25, 2026
10w ago
S-3
BEARISH ★ 6/10
$15.13 $12.51▲ +17.32%▲ +18.95%$9.74 (+35.59%)
Mar 18, 2026
11w ago
S-3
BEARISH ★ 7/10
$18.21 $15.13▲ +16.91%▲ +14.70%$9.74 (+46.49%)
Showing 5 of 5

US Market Status

Market Closed — Opens Thu (10h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access